78
Participants
Start Date
May 29, 2019
Primary Completion Date
February 16, 2023
Study Completion Date
February 16, 2023
XmAb®22841
Monoclonal bispecific antibody
Pembrolizumab (Keytruda®)
FDA-approved humanized monoclonal antibody
Laura & Isaac Perlmutter Cancer Center at NYU Langone Health, New York
NYU Langone Medical Center (Tisch Hospital), New York
Columbia University Medical Center, New York
UPMC Hillman Cancer Center, Pittsburgh
UPMC Shadyside Hospital, Pittsburgh
Hospital of the University of Pennsylvania - Perelman Center for Advanced Medicine, Philadelphia
Emory University Hospital Midtown, Atlanta
Winship Cancer Institute, Emory University, Atlanta
University of Michigan Medical School, Ann Arbor
Karmanos Cancer Institute, Detroit
Karmanos Cancer Institute Weisberg Cancer Treatment Center, Farmington Hills
University of Iowa Hospital and Clinics, Iowa City
Mary Crowley Cancer Research - Medical City, Dallas
The University of Texas MD Anderson Cancer Center, Houston
University of Utah, Huntsman Cancer Institute, Salt Lake City
UCLA Hematology & Oncology Clinic, Los Angeles
UCSD Medical Center - Encinitas, Encinitas
Koman Family Outpatient Pavilion, La Jolla
UC San Diego Medical Center - La Jolla (Jacobs Medical Center / Thornton Pavilion), La Jolla
UCSD Altman Clinical and Translational Research Institute Building (ACTRI), La Jolla
UCSD Perlman Medical Offices, La Jolla
UCSD Medical Center - Vista, Vista
UC San Diego Moores Cancer Center, La Jolla
UC San Diego Medical Center - Hillcrest, San Diego
UCSD Rancho Bernardo Medical Office, San Diego
Brigham and Women's Hospital, Boston
Dana-Farber Cancer Institute, Boston
Brigham and Women's Health Care Center, Chestnut Hill, Chestnut Hill
Collaborators (1)
ICON Clinical Research
INDUSTRY
Xencor, Inc.
INDUSTRY